the combination therapy of TGF-β compared with TGF, 1 + hepaCAM significantly down-regulated p-SMAD2/3, procaspase 3/8/9 and PARP, and induced bladder cancer cell apoptosis-β alone. Here, SMAD2 is linked to urinary bladder cancer.